Episode Summary
Executive Summary: Brian Singerman of Founders Fund argues venture capital is about maximizing upside by investing heavily in the best founders and companies at the best price, not chasing macro forecasts or structured downside protection. He explains why Founders Fund slowed in 2022, how pricing dislocations constrain deals, why brand, sourcing, and unique team strengths matter, and why defense tech—especially Anduril—fits their highest-conviction model.
Main Topics: Core venture philosophy: upside maximization (Priority: 5/5): Singerman repeatedly frames venture as a game of putting as much capital as possible into the best companies at the best prices, rather than optimizing for downside protection or macro timing. Macro, pricing dislocations, and the 2022 reset (Priority: 5/5): He says macro matters because private-company pricing lags public markets, but he rejects predictions. The 2022 downturn created a major mismatch that made many attractive deals uneconomic. Founders Fund’s deployment discipline and selectivity (Priority: 5/5): He says the firm can wait, has no pressure to deploy capital, and only acts when it can invest in top companies at reasonable prices—otherwise it passes. Sourcing, selection, and access as equal pillars (Priority: 4/5): Singerman argues venture success depends equally on seeing the right companies, picking the right ones, and getting into the deal. Brand helps access, but sourcing is the hardest part as networks age. Cross-fund investing and fund sizing (Priority: 4/5): He defends large checks and cross-fund investing in exceptional companies, arguing that top firms should reuse conviction across multiple funds and raise fund sizes only if they can write meaningful checks. Team-building, unique moats, and non-clone hiring (Priority: 4/5): Founders Fund hires people with differentiated strengths rather than clones, and Singerman sees similar value in founders and partners who have a truly unique angle. Anduril, defense tech, and conviction investing (Priority: 5/5): He uses Anduril as the clearest example of a massive moat: a unique team, product talent, government relationships, and a market newly open to Silicon Valley innovation.
Key Arguments: Venture is not about buy-low-sell-high in the stock-market sense; it is about owning upside in exceptional private companies over a long horizon. Macro should be watched because private markets lag public markets, but no one can reliably predict it, so investors should not pretend they can. Founders Fund intentionally slowed deployment in 2022 because the best companies were not willing to raise at current market prices. The firm has no pressure to deploy capital quickly because its LPs trust its judgment and its prior performance gives it flexibility. Large checks make sense only when the company is truly exceptional; small checks in giant funds are poor fit for the firm’s model. Cross-fund investing is acceptable when a company is strong enough to justify additional capital across multiple funds, and LPs benefit from it. Success in venture requires equal competence in sourcing, picking, and winning deals; the best brand helps with access but not with judgment. The firm’s edge comes from being adaptable, avoiding dogma, and hiring people with distinct strengths rather than generalists. Board work is not Singerman’s strength; he prefers strategy dinners and direct founder conversations over governance-heavy boardroom involvement. Anduril exemplifies Founders Fund’s thesis: a unique team, a large underserved market, and a new wave of defense innovation.
Data Points: Years at Founders Fund: Almost 15 years - Singerman describes his tenure and career path into venture Year discussion took place: October 2022 - Used as the macro context for pricing dislocation and fundraising conditions Big check into Anduril: $200 million - He cites this as the only major check he did in 2022 Total capital in Anduril: $400 million - He says the recent $200 million check brought total investment to this amount Founders Fund annual private financings: More than 1,300 - Mentioned in sponsor read about Cooley’s startup/VC practice Tegus expert call pricing: Average of $300 per call - Sponsor segment describing Tegus expert calls MarketX covered companies: Over 300 pre-IPO companies - Sponsor segment describing MarketX platform MarketX portfolio/company interactions: More than 50 growth to late-stage portfolio companies - Sponsor segment describing MarketX experience MarketX 2021 exits: Five IPOs and acquisitions - Sponsor segment about MarketX track record in 2021 Founders Fund preferred check sizing: $200M to $500M range in exceptional cases - Singerman explains his comfort with very large conviction checks Advice to new managers: Raise small enough to write 25% to 30% of fund size in a single check - He recommends sizing funds around the ability to make meaningful concentrated investments
Pivotal Quotes: "Put the most money possible into the best companies possible at the best price possible. That's venture capital." — Brian Singerman: Defines his entire venture investing philosophy and the episode’s central thesis "I don't pontificate. Here's what I do: I have a really, what I think is a pretty good knack of picking the best founders, doing things that have a potential to be very outsized." — Brian Singerman: Explains his self-conception as a pragmatic, conviction-driven investor rather than a macro theorist "We only want to invest in the best companies, right? ... We have no pressure to invest capital." — Brian Singerman: Describes Founders Fund’s selectivity during the 2022 pricing reset
Implications: For investors, the message is to focus on conviction, pricing discipline, and sourcing edge—not macro theater. For founders, the bar is higher: raise on reasonable terms or wait. For the industry, large funds and elite firms will keep favoring exceptional teams in huge markets, especially in defense and deep tech.